Zymeworks (ZYME)
Market Price (2/21/2026): $22.5 | Market Cap: $1.7 BilSector: Health Care | Industry: Biotechnology
Zymeworks (ZYME)
Market Price (2/21/2026): $22.5Market Cap: $1.7 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -14% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -71 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -52% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 116% | Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 18% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. | Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -48%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -49% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.0% | |
| Key risksZYME key risks include [1] the potential clinical and regulatory failure of its lead product candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -14% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 116% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more. |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -71 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -52% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 18% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -48%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -49% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -8.0% |
| Key risksZYME key risks include [1] the potential clinical and regulatory failure of its lead product candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Zymeworks (ZYME) stock has gained about 20% since 10/31/2025 because of the following key factors:
1. Positive Phase 3 Results for Ziihera (zanidatamab-hrii) in GEA.
Zymeworks reported positive Phase 3 results for its lead product candidate, Ziihera (zanidatamab-hrii), in first-line HER2-positive gastroesophageal adenocarcinoma (GEA) at the ASCO Gastrointestinal Cancers Symposium. The trial demonstrated a statistically significant improvement in progression-free survival compared to standard treatment, indicating a potential advancement in the treatment of this difficult-to-treat cancer.
2. Potential for Significant Milestone Payments from Ziihera Regulatory Approvals.
Following the positive Phase 3 results, Zymeworks outlined the potential to receive up to $440 million in milestone payments contingent on regulatory approvals of Ziihera in GEA across key global markets. This includes $250 million from the United States, $100 million from Europe, $75 million from Japan, and $15 million from China. Partner Jazz Pharmaceuticals plans to submit a supplemental Biologics License Application (sBLA) for zanidatamab in the U.S. during the first half of 2026, providing a clear pathway for these potential payments.
Show more
1. Positive Phase 3 Results for Ziihera (zanidatamab-hrii) in GEA.
Zymeworks reported positive Phase 3 results for its lead product candidate, Ziihera (zanidatamab-hrii), in first-line HER2-positive gastroesophageal adenocarcinoma (GEA) at the ASCO Gastrointestinal Cancers Symposium. The trial demonstrated a statistically significant improvement in progression-free survival compared to standard treatment, indicating a potential advancement in the treatment of this difficult-to-treat cancer.
2. Potential for Significant Milestone Payments from Ziihera Regulatory Approvals.
Following the positive Phase 3 results, Zymeworks outlined the potential to receive up to $440 million in milestone payments contingent on regulatory approvals of Ziihera in GEA across key global markets. This includes $250 million from the United States, $100 million from Europe, $75 million from Japan, and $15 million from China. Partner Jazz Pharmaceuticals plans to submit a supplemental Biologics License Application (sBLA) for zanidatamab in the U.S. during the first half of 2026, providing a clear pathway for these potential payments.
Show more
Stock Movement Drivers
Fundamental Drivers
The 19.0% change in ZYME stock from 10/31/2025 to 2/20/2026 was primarily driven by a 9.5% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.09 | 22.72 | 19.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 123 | 134 | 9.5% |
| P/S Multiple | 11.7 | 12.8 | 9.4% |
| Shares Outstanding (Mil) | 75 | 76 | -0.6% |
| Cumulative Contribution | 19.0% |
Market Drivers
10/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| ZYME | 19.0% | |
| Market (SPY) | 1.1% | 4.2% |
| Sector (XLV) | 8.7% | 18.4% |
Fundamental Drivers
The 80.9% change in ZYME stock from 7/31/2025 to 2/20/2026 was primarily driven by a 44.0% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 12.56 | 22.72 | 80.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 93 | 134 | 44.0% |
| P/S Multiple | 10.1 | 12.8 | 26.6% |
| Shares Outstanding (Mil) | 75 | 76 | -0.8% |
| Cumulative Contribution | 80.9% |
Market Drivers
7/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| ZYME | 80.9% | |
| Market (SPY) | 9.4% | 7.1% |
| Sector (XLV) | 20.8% | 18.7% |
Fundamental Drivers
The 55.6% change in ZYME stock from 1/31/2025 to 2/20/2026 was primarily driven by a 116.2% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312025 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.60 | 22.72 | 55.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 62 | 134 | 116.2% |
| P/S Multiple | 17.9 | 12.8 | -28.4% |
| Shares Outstanding (Mil) | 76 | 76 | 0.5% |
| Cumulative Contribution | 55.6% |
Market Drivers
1/31/2025 to 2/20/2026| Return | Correlation | |
|---|---|---|
| ZYME | 55.6% | |
| Market (SPY) | 15.6% | 23.2% |
| Sector (XLV) | 8.2% | 29.5% |
Fundamental Drivers
The 140.4% change in ZYME stock from 1/31/2023 to 2/20/2026 was primarily driven by a 350.4% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312023 | 2202026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.45 | 22.72 | 140.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 30 | 134 | 350.4% |
| P/S Multiple | 21.0 | 12.8 | -39.2% |
| Shares Outstanding (Mil) | 66 | 76 | -12.3% |
| Cumulative Contribution | 140.4% |
Market Drivers
1/31/2023 to 2/20/2026| Return | Correlation | |
|---|---|---|
| ZYME | 140.4% | |
| Market (SPY) | 75.9% | 25.6% |
| Sector (XLV) | 23.1% | 25.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ZYME Return | -65% | -52% | 32% | 41% | 80% | -11% | -51% |
| Peers Return | -9% | -24% | -0% | -9% | 23% | 16% | -9% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 0% | 83% |
Monthly Win Rates [3] | |||||||
| ZYME Win Rate | 33% | 50% | 50% | 75% | 58% | 50% | |
| Peers Win Rate | 38% | 40% | 46% | 48% | 52% | 88% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ZYME Max Drawdown | -68% | -72% | -21% | -22% | -36% | -16% | |
| Peers Max Drawdown | -20% | -48% | -38% | -24% | -29% | -1% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MGNX, ADCT, AMGN, GILD.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/20/2026 (YTD)
How Low Can It Go
| Event | ZYME | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -91.8% | -25.4% |
| % Gain to Breakeven | 1121.7% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -51.2% | -33.9% |
| % Gain to Breakeven | 105.1% | 51.3% |
| Time to Breakeven | 256 days | 148 days |
| 2018 Correction | ||
| % Loss | -51.2% | -19.8% |
| % Gain to Breakeven | 104.9% | 24.7% |
| Time to Breakeven | 178 days | 120 days |
Compare to MGNX, ADCT, AMGN, GILD
In The Past
Zymeworks's stock fell -91.8% during the 2022 Inflation Shock from a high on 1/8/2021. A -91.8% loss requires a 1121.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Zymeworks (ZYME)
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
AI Analysis | Feedback
Here are 1-3 brief analogies for Zymeworks (ZYME):
- Like Seagen (a major player in antibody-drug conjugates), but also developing innovative 'two-target' antibody therapies (bispecifics) for cancer.
- Like a specialized, 'next-generation' Genentech (pioneer of targeted cancer biologics) focused on engineering advanced 'smart' antibody therapies like bispecifics and antibody-drug conjugates.
AI Analysis | Feedback
- Zanidatamab: A HER2-targeted bispecific antibody currently in late-stage clinical development for various HER2-expressing cancers.
- Bispecific Antibodies: A portfolio of preclinical and early-stage antibody candidates engineered to target multiple disease pathways simultaneously for cancer treatment.
- Antibody-Drug Conjugates (ADCs): A pipeline of preclinical and early-stage drug candidates designed to deliver potent chemotherapy directly to cancer cells.
AI Analysis | Feedback
Zymeworks (ZYME) is a clinical-stage biopharmaceutical company that primarily sells its technology and drug candidates to other companies, specifically larger pharmaceutical and biotechnology firms, through licensing agreements and collaborations. They do not sell directly to individuals.
Its major customers and partners include:
- Jazz Pharmaceuticals (Symbol: JAZZ) - Jazz holds exclusive rights for the development and commercialization of Zymeworks' lead product candidate, zanidatamab, in the United States, Europe, Japan, and other territories outside of Asia (excluding Japan). They also have a separate collaboration for other therapeutic candidates utilizing Zymeworks' platforms.
- Merck & Co., Inc. (Symbol: MRK) - Merck has a license agreement for the research, development, and commercialization of therapeutic candidates using Zymeworks' Azymetricâ„¢ and ZymeLinkâ„¢ platforms.
- BeiGene, Ltd. (Symbol: BGNE) - BeiGene retains rights to develop and commercialize two bispecific antibody programs utilizing Zymeworks' Azymetricâ„¢ platform in Asia (excluding Japan), Australia, and New Zealand.
AI Analysis | Feedback
nullAI Analysis | Feedback
Kenneth Galbraith, Chair & CEO Mr. Galbraith has served as Zymeworks' Chief Executive Officer and Chair of its board of directors since January 2022, and as President since June 2023. He has over 35 years of experience in biotechnology and venture capital, working with both private and NASDAQ-listed companies. Mr. Galbraith founded Five Corners Capital, Inc. in 2013, and previously managed the Ventures West Investment Funds. He was Executive Chair of AnorMED, which was acquired by Genzyme for $584 million. He has also been involved with other biotechnology companies that were sold, including Alder Pharmaceuticals (sold to Lundbeck), Celator Pharmaceuticals (sold to Jazz Pharma), Novadaq (sold to Stryker), and Fairhaven Pharmaceuticals (sold to Liminal Bio). He served as Executive in Residence and later as Chair for Syncona Investment Management Limited, a firm focused on building life sciences businesses. Leone Patterson, Executive Vice President, Chief Business and Financial Officer Ms. Patterson joined Zymeworks in September 2024. Prior to Zymeworks, she was Chief Financial and Business Officer of Tenaya Therapeutics, Inc. from June 2021 until August 2024. She also held leadership roles at Adverum Biotechnologies, including Chief Financial Officer, President, Chief Executive Officer, and Director. Her career includes senior finance positions at Diadexus, Transcept, Exelixis, Novartis, and Chiron, and she previously worked in the audit practice of KPMG. Ms. Patterson currently serves on the board of directors for Nkarta, Inc. and Oxford Biomedica, both publicly-held companies. Paul Moore, Chief Scientific Officer Dr. Moore joined Zymeworks in July 2022. He brings more than 25 years of U.S.-based experience in biologics drug discovery and development in biotechnology research. Before joining Zymeworks, Dr. Moore served as Vice President, Cell Biology, and Immunology at MacroGenics. His earlier career at Human Genome Sciences (HGS) involved managing genomic-based target discovery programs that led to the discovery, development, approval, and commercialization of Benlysta; HGS was subsequently acquired by GlaxoSmithKline (GSK) for $3.6 billion. Jeffrey Smith, Executive Vice President and Chief Medical Officer Dr. Smith joined Zymeworks in January 2023 as Senior Vice President, Early Stage Development, and was promoted to Executive Vice President and Chief Medical Officer in January 2024. He previously served as the Managing Director of Alder Biopharmaceuticals Inc. in Dublin, Ireland, and as Senior Vice President, Translational Medicine for Alder Biopharmaceuticals Inc. in Seattle, USA. Adam Schayowitz, Acting Chief Development Officer Dr. Schayowitz has served as Zymeworks' Acting Chief Development Officer since October 2025. He has nearly 20 years of experience in oncology drug development, having led numerous global development programs from initiation through approval and commercialization. Prior to Zymeworks, he was a Vice President at Pfizer Oncology, where he held various development leadership roles, including serving as Head of Product Development Teams.AI Analysis | Feedback
Here are the key risks to Zymeworks' business:
- Clinical Trial and Regulatory Risks: As a clinical-stage biopharmaceutical company, Zymeworks' success is heavily contingent on the successful development, regulatory approval, and commercialization of its product candidates. There is no assurance that its product candidates, such as zanidatamab, will meet primary endpoints in clinical trials with statistical significance, or that the data will be sufficient to secure regulatory approvals. The discontinuation of clinical development for ZW171 due to an unfavorable benefit-risk profile underscores the inherent challenges and uncertainties in drug development. Failures or delays in clinical trials or regulatory processes could significantly impede the company's ability to bring products to market.
- Dependence on Partnerships and Milestone Payments: Zymeworks relies significantly on strategic partnerships with larger pharmaceutical companies, such as Jazz Pharmaceuticals and BeiGene, for the development and commercialization of its lead product candidate, zanidatamab, and other pipeline assets. A substantial portion of Zymeworks' anticipated revenue and future funding is derived from milestone payments and royalties from these collaboration agreements. There is a risk that Zymeworks may not achieve these milestones or receive the expected payments, or that partners could choose to terminate their agreements, which would materially impact the company's financial condition and projected revenue.
- Financial Sustainability and Need for Additional Funding: Zymeworks currently operates at a net loss and has a negative free cash flow, typical for a clinical-stage biotechnology company. While the company has projected cash resources to fund operations into the second half of 2027, its long-term financial requirements are substantial. These needs are dependent on the scope, rate of progress, results, and costs of its clinical trials and preclinical studies, as well as the successful achievement of milestones through its partnerships. Zymeworks will require additional funding to support its ongoing operations and long-term business plans, and its ability to obtain such funding is not guaranteed.
AI Analysis | Feedback
nullAI Analysis | Feedback
Zymeworks (NASDAQ: ZYME) Addressable Markets for Main Products:
Zymeworks' primary product in advanced development is zanidatamab (also known as Ziihera), a HER2-targeted bispecific antibody. The company also has other pipeline candidates in earlier stages, including ZW191 and ZW251.
Zanidatamab (Ziihera):
- HER2-positive Biliary Tract Cancer (BTC):
- The global biliary tract cancers treatment market is projected to grow from USD 372.5 million in 2025 to USD 824.2 million by 2035. Other estimates for the global market include USD 696.75 million in 2023, expected to reach USD 1.42 billion in 2030, and approximately USD 1000 million in 2023.
- In North America, the bile duct cancer market is expected to exceed USD 2.7 billion by 2032. The United States market for biliary tract cancers treatment is projected to maintain an 8.2% Compound Annual Growth Rate (CAGR) from 2025 to 2035.
- HER2-positive Gastroesophageal Adenocarcinoma (GEA):
- The market opportunity for GEA is estimated at $2 billion. The broader HER2-positive gastrointestinal cancers market is estimated at $4 billion annually.
- The global HER2-positive gastric cancer market is projected to grow from USD 1304.5 million in 2023 to USD 1700.59 million in 2031. The global stomach cancer treatment market, which includes GEA, was estimated at USD 5,369.6 million in 2024 and is projected to reach USD 11,194.9 million by 2030. Another source indicates the global stomach cancer treatment market is forecasted to reach around USD 17.60 billion by 2034.
- The global esophageal cancer therapeutics market was valued at USD 2.93 billion in 2024 and is projected to grow to USD 5.95 billion by 2032.
- HER2-positive Metastatic Breast Cancer (mBC):
- The global HER2-Positive Breast Cancer Market is estimated at USD 10.96 billion in 2025 and is expected to reach USD 12.94 billion by 2032. Another report states the market size grew from $10.21 billion in 2024 to $10.96 billion in 2025, and is expected to reach $14.41 billion in 2029.
- The total metastatic HER2-positive breast cancer market size in the seven major markets (7MM: United States, EU4, United Kingdom, and Japan) was estimated at nearly USD 2.6 billion in 2022 and is expected to reach USD 3,108.1 million by 2035.
- HER2-low Cancers:
- The HER2-low cancers market across the 7MM (United States, EU4, United Kingdom, and Japan) is valued at approximately USD 3,530 million in 2025 and is projected to reach approximately USD 8,997 million by 2034. The total market size for HER2-low cancers in the 7MM was USD 3.2 billion in 2024.
- The global HER2-Low Breast Cancer Therapies market size in 2024 is valued at USD 2.23 billion, projected to reach USD 6.08 billion by 2033.
ZW191:
- ZW191 is an antibody-drug conjugate (ADC) targeting folate receptor-alpha (FRα) for advanced solid tumors, including gynecological cancers (ovarian and endometrial) and non-small cell lung cancer. Zymeworks is currently conducting Phase 1 studies for ZW191.
- No specific addressable market size for ZW191 or FRα-targeted therapies was identified in the provided search results.
ZW251:
- ZW251 is an ADC engineered to target glypican-3 (GPC3) for hepatocellular carcinoma (HCC).
- Hepatocellular Carcinoma (HCC):
- The global hepatocellular carcinoma drugs market was valued at USD 1.21 billion in 2024 and is expected to reach USD 2.27 billion by 2032. Other estimates for the global market include US$977 million in 2022, expected to reach US$2.4 billion by 2030, and USD 3.5 billion in 2024, projected to reach USD 9.85 billion by the end of 2030.
- The hepatocellular carcinoma market across the top 7 markets (US, EU4, UK, and Japan) reached a value of USD 830 million in 2024 and is expected to reach USD 1,650 million by 2035.
- The global unresectable hepatocellular carcinoma market was USD 2,528.2 million in 2025 and is expected to grow to approximately USD 4,927.0 million by 2035.
ZW171:
- Zymeworks has discontinued the clinical development of ZW171, a T cell engager targeting mesothelin-expressing cancers, due to safety concerns. Therefore, there is no addressable market for this product.
AI Analysis | Feedback
Zymeworks (ZYME) is expected to drive future revenue growth over the next 2-3 years through a combination of strategic partnerships, the expanded commercialization of its lead product, and the advancement of its pipeline. Here are 3-5 expected drivers of future revenue growth:- Increasing Milestone Payments from Partnerships: Zymeworks has a partnership-driven business model that generates significant milestone revenue. The company recognized a $25 million development milestone from Johnson & Johnson in Q3 2025, and $14 million from GSK and $3.1 million from Daiichi Sankyo in Q1 2025. Zymeworks remains eligible to receive up to an additional $434 million in development and commercial milestones from the Johnson & Johnson collaboration, along with other potential milestones from existing and new partnerships. These payments are anticipated to continue contributing to Zymeworks' revenue stream.
- Growing Royalty Revenue from Zanidatamab Sales: Zanidatamab, Zymeworks' HER2-targeted bispecific antibody, has received accelerated approval from the U.S. FDA for previously treated HER2-positive biliary tract cancer (BTC) in November 2024. It also received conditional marketing authorization from the European Commission in July 2025. Regulatory reviews are ongoing in China. As commercialization efforts by partners Jazz Pharmaceuticals and BeiGene expand, Zymeworks expects to see a predictable and substantial increase in royalty revenues from net product sales of zanidatamab across these territories.
- Expansion of Zanidatamab into New Indications: Beyond BTC, zanidatamab is being evaluated in a global Phase 3 study (HERIZON-GEA-01) for first-line HER2-positive gastroesophageal adenocarcinoma (GEA). Top-line results from this trial are anticipated in the second quarter of 2025, with a potential supplemental Biologics License Application (sBLA) by Jazz Pharmaceuticals later that year. Additionally, a Phase 2 trial (EmpowHER-BC-208) has been initiated to evaluate zanidatamab in HER2-positive neoadjuvant and adjuvant breast cancer. Successful clinical development and regulatory approvals in these larger indications would significantly broaden zanidatamab's market potential and substantially increase future royalty income.
- Advancement of Wholly-Owned Pipeline Programs: Zymeworks is progressing its internal pipeline of novel therapeutics. ZW191, a folate receptor alpha-directed ADC, has shown promising Phase 1 data, with dose-optimization in ovarian cancer expected to commence in Q4 2025. The company has also dosed the first patient in a Phase 1 trial for ZW251, a GPC3-targeted ADC for hepatocellular carcinoma. Further investigational new drug (IND) applications are anticipated for ZW220 and ZW251 in 2025, and for ZW209 and ZW1528 in 2026. Progression of these wholly-owned assets could lead to new partnership agreements, additional milestone payments, and eventual commercialization, contributing to long-term revenue growth.
AI Analysis | Feedback
Share Repurchases
- Zymeworks' Board of Directors authorized a Share Repurchase Program of up to $60.0 million of its outstanding common stock in August 2024.
- The company intended to commence the Share Repurchase Program with $30.0 million in initial repurchases during the second half of 2024, reserving the remaining $30.0 million for future repurchases.
- As of November 4, 2025, Zymeworks had completed $22.7 million of the previously approved share repurchase program.
Share Issuance
- As of March 4, 2024, Zymeworks had 70,568,222 outstanding common shares.
- The company completed a $50 million private placement to EcoR1 Capital in December 2023, with proceeds intended to extend its cash runway into the second half of 2027.
Inbound Investments
- Zymeworks achieved a $25.0 million development milestone from Johnson & Johnson Innovative Medicine in September 2025, associated with pasritamig entering a Phase 3 trial.
- The company earned $1.0 million in royalty revenue from partners Jazz and BeOne Medicines in the third quarter of 2025, driven by net product sales of Ziihera®.
- Under an amended agreement with Jazz Pharmaceuticals, Zymeworks has received an aggregate of $375 million in proceeds to date (as of early 2024) and remains eligible for up to $525 million in regulatory milestones and up to $862.5 million in potential commercial milestone payments, plus tiered royalties.
Outbound Investments
- No significant outbound investments with specified dollar amounts within the last 3-5 years were identified in the available information.
Capital Expenditures
- Zymeworks' capital expenditures were $4.31 million in 2020, $12 million in 2021, $8.15 million in 2022, $2.47 million in 2023, and $1.99 million in 2024.
- The forecast mean consensus for capital expenditures for the next fiscal year is $5.5 million.
- A significant portion of Zymeworks' expenditure is allocated to Research and Development (R&D) to advance its pipeline of novel therapies.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Zymeworks Earnings Notes | 12/31/2026 | |
| With Zymeworks Stock Surging, Have You Considered The Downside? | 10/17/2025 | |
| Zymeworks (ZYME) Operating Income Comparison | 08/09/2025 | |
| Zymeworks (ZYME) Net Income Comparison | 08/09/2025 | |
| Zymeworks (ZYME) Debt Comparison | 08/09/2025 | |
| Zymeworks (ZYME) Operating Cash Flow Comparison | 08/09/2025 | |
| Zymeworks (ZYME) Revenue Comparison | 08/09/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to ZYME.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 01302026 | VEEV | Veeva Systems | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | -14.6% | -14.6% | -15.7% |
| 01162026 | BIIB | Biogen | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 19.5% | 19.5% | 0.0% |
| 01162026 | BMRN | BioMarin Pharmaceutical | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 9.7% | 9.7% | 0.0% |
| 01162026 | DOCS | Doximity | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | -39.4% | -39.4% | -40.1% |
| 01022026 | CORT | Corcept Therapeutics | Dip Buy | DB | CFO/Rev | Low D/EDip Buy with High Cash Flow MarginsBuying dips for companies with significant cash flows from operations and reasonable debt / market cap | 4.6% | 4.6% | -9.1% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 22.72 |
| Mkt Cap | 1.7 |
| Rev LTM | 134 |
| Op Inc LTM | -71 |
| FCF LTM | -66 |
| FCF 3Y Avg | 22 |
| CFO LTM | -64 |
| CFO 3Y Avg | 25 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.4% |
| Rev Chg 3Y Avg | 11.9% |
| Rev Chg Q | 3.0% |
| QoQ Delta Rev Chg LTM | 0.8% |
| Op Mgn LTM | -52.5% |
| Op Mgn 3Y Avg | -67.6% |
| QoQ Delta Op Mgn LTM | 0.9% |
| CFO/Rev LTM | -47.8% |
| CFO/Rev 3Y Avg | -31.1% |
| FCF/Rev LTM | -49.2% |
| FCF/Rev 3Y Avg | -34.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.7 |
| P/S | 6.5 |
| P/EBIT | -1.5 |
| P/E | -1.4 |
| P/CFO | -0.7 |
| Total Yield | -3.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 5.6% |
| D/E | 0.2 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 9.8% |
| 3M Rtn | 11.8% |
| 6M Rtn | 29.4% |
| 12M Rtn | 41.4% |
| 3Y Rtn | 72.8% |
| 1M Excs Rtn | 9.3% |
| 3M Excs Rtn | 6.0% |
| 6M Excs Rtn | 21.2% |
| 12M Excs Rtn | 32.1% |
| 3Y Excs Rtn | 3.7% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Biotherapeutics segment | 76 | ||||
| Research and development collaborations | 412 | 27 | 39 | 30 | |
| Total | 76 | 412 | 27 | 39 | 30 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Impairment | 0 | ||||
| Change in contingent consideration | -1 | ||||
| Stock-based compensation expense | -8 | ||||
| Depreciation and amortization | -10 | ||||
| Biotherapeutics segment | -119 | ||||
| Total | -138 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Biotherapeutics segment | -119 | ||||
| Total | -119 |
Price Behavior
Price Behavior
| Market Price | $22.72 | |
| Market Cap ($ Bil) | 1.7 | |
| First Trading Date | 04/28/2017 | |
| Distance from 52W High | -17.7% | |
| 50 Days | 200 Days | |
| DMA Price | $24.30 | $17.82 |
| DMA Trend | up | up |
| Distance from DMA | -6.5% | 27.5% |
| 3M | 1YR | |
| Volatility | 41.4% | 57.2% |
| Downside Capture | 55.41 | 81.25 |
| Upside Capture | 9.46 | 119.88 |
| Correlation (SPY) | 16.1% | 24.1% |
ZYME Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -1.26 | -0.46 | 0.09 | 0.30 | 0.70 | 0.84 |
| Up Beta | 0.19 | 1.45 | 4.72 | 2.74 | 0.53 | 0.76 |
| Down Beta | -1.63 | -1.36 | -1.67 | -1.85 | 0.64 | 0.86 |
| Up Capture | -250% | -96% | 32% | 148% | 119% | 90% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 10 | 21 | 30 | 64 | 127 | 374 |
| Down Capture | 39% | 54% | -79% | -25% | 86% | 94% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 10 | 20 | 31 | 61 | 122 | 367 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ZYME | |
|---|---|---|---|---|
| ZYME | 51.3% | 57.5% | 0.92 | - |
| Sector ETF (XLV) | 8.6% | 17.3% | 0.32 | 29.9% |
| Equity (SPY) | 13.5% | 19.4% | 0.53 | 24.0% |
| Gold (GLD) | 74.5% | 25.6% | 2.15 | 0.2% |
| Commodities (DBC) | 7.2% | 16.9% | 0.25 | 1.8% |
| Real Estate (VNQ) | 7.1% | 16.7% | 0.24 | 21.6% |
| Bitcoin (BTCUSD) | -30.6% | 44.9% | -0.68 | 13.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ZYME | |
|---|---|---|---|---|
| ZYME | -11.4% | 62.8% | 0.07 | - |
| Sector ETF (XLV) | 7.6% | 14.5% | 0.34 | 19.6% |
| Equity (SPY) | 13.4% | 17.0% | 0.62 | 25.2% |
| Gold (GLD) | 22.6% | 17.1% | 1.08 | 3.2% |
| Commodities (DBC) | 10.9% | 19.0% | 0.46 | 1.4% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 18.6% |
| Bitcoin (BTCUSD) | 7.2% | 57.1% | 0.35 | 18.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ZYME | |
|---|---|---|---|---|
| ZYME | 5.6% | 62.1% | 0.36 | - |
| Sector ETF (XLV) | 11.3% | 16.5% | 0.57 | 24.0% |
| Equity (SPY) | 16.1% | 17.9% | 0.77 | 27.5% |
| Gold (GLD) | 14.8% | 15.6% | 0.79 | 3.7% |
| Commodities (DBC) | 8.6% | 17.6% | 0.40 | 7.2% |
| Real Estate (VNQ) | 7.0% | 20.7% | 0.30 | 20.2% |
| Bitcoin (BTCUSD) | 67.8% | 66.7% | 1.07 | 11.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 11/6/2025 | -8.0% | 3.4% | 44.2% |
| 8/7/2025 | -1.2% | 17.6% | 24.9% |
| 3/5/2025 | -8.0% | -6.8% | -10.8% |
| 10/31/2024 | -3.1% | 22.4% | 5.8% |
| 8/1/2024 | 0.9% | 0.9% | 16.0% |
| 3/6/2024 | -6.5% | -12.1% | -21.1% |
| 11/7/2023 | -3.7% | 3.5% | 29.6% |
| 8/10/2023 | -7.6% | -5.3% | -9.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 2 | 7 | 6 |
| # Negative | 8 | 3 | 4 |
| Median Positive | 0.7% | 6.4% | 21.6% |
| Median Negative | -5.1% | -6.8% | -10.3% |
| Max Positive | 0.9% | 22.4% | 44.2% |
| Max Negative | -8.0% | -12.1% | -21.1% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/06/2025 | 10-Q |
| 06/30/2025 | 08/07/2025 | 10-Q |
| 03/31/2025 | 05/08/2025 | 10-Q |
| 12/31/2024 | 03/05/2025 | 10-K |
| 09/30/2024 | 10/31/2024 | 10-Q |
| 06/30/2024 | 08/01/2024 | 10-Q |
| 03/31/2024 | 05/02/2024 | 10-Q |
| 12/31/2023 | 03/06/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/10/2023 | 10-Q |
| 03/31/2023 | 05/08/2023 | 10-Q |
| 12/31/2022 | 03/07/2023 | 10-K |
| 09/30/2022 | 11/08/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
| 12/31/2021 | 02/24/2022 | 10-K |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Smith, Jeffrey T L | EVP & Chief Medical Officer | Direct | Sell | 1052026 | 25.10 | 10,538 | 264,471 | 460,578 | Form |
| 2 | Galbraith, Kenneth | Chair & CEO | Direct | Sell | 1052026 | 25.10 | 54,343 | 1,363,841 | 3,972,488 | Form |
| 3 | Moore, Paul Andrew | Chief Scientific Officer | Direct | Sell | 1052026 | 25.10 | 20,110 | 504,699 | 783,324 | Form |
| 4 | Galbraith, Kenneth | Chair & CEO | Direct | Sell | 12222025 | 27.02 | 47,528 | 1,284,311 | 3,601,384 | Form |
| 5 | Ecor1, Capital, Llc | See Note | Buy | 5192025 | 11.43 | 49,502 | 565,847 | 204,359,717 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.